ERBB2 and hepatocellular carcinoma: The anti-Her2 ADCs showed potent dose dependent in vitro cytotoxicity against the HCC-1954 and NCI-N87 cell lines and no in vitro cytotoxicity on the MDA-MB-468 cell line was observed.